Still not enough women and older adults in cholesterol drug trials, study finds

Although heart disease is the leading cause of death in women, and older adults are more likely to have heart and vascular disease than young people, randomized clinical trials testing medications to lower cholesterol have historically underenrolled both groups. Randomized clinical trials generate the best evidence regarding the benefits or harms of given drug, and…

Details

RIHN taking initiative on discussion toward ‘new life’ after COVID-19 pandemic

The initiative of Covid-19 and Sustainable Transitions was inspired by a blog by the leadership of the Systems of Sustainable Consumption and Production Knowledge-Action Network and began in late-March in the form of an interactive online Open Forum, which has now developed into a diverse community of over 100 people including scientists, economists, and educators.…

Details

No evidence blanket ‘do-not-resuscitate’ orders for COVID-19 patients are necessary

DALLAS, May 22, 2020 — It’s inappropriate to consider blanket do-not-resuscitate orders for COVID-19 patients because adequate data is not yet available on U.S. survival rates for in-hospital resuscitation of COVID-19 patients and data from China may not relate to U.S. patients, according to a new article published today in Circulation: Cardiovascular Quality and Outcomes,…

Details

Glucose levels linked to maternal mortality even in non-diabetic women

An elevated pre-pregnancy hemoglobin A1c–which measures average blood glucose concentration–is associated with a higher risk of adverse pregnancy outcomes even in women without known diabetes, according to a new study published this week in PLOS Medicine by Joel Ray of ICES and the University of Toronto, Canada, and colleagues. Diabetes mellitus and obesity are both…

Details

The Lancet: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response

The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet. The open-label trial in 108 healthy adults demonstrates promising results after 28 days–the final results will be evaluated in…

Details

The Lancet: No evidence of benefit for chloroquine and hydroxychloroquine in COVID-19 patients

A large observational study suggests that treatment with the antimalarial drug chloroquine or its analogue hydroxychloroquine (taken with or without the antibiotics azithromycin or clarithromycin) offers no benefit for patients with COVID-19. The study analysed data from nearly 15,000 patients with COVID-19 receiving a combination of any of the four drug regimens and 81,000 controls.…

Details

£7 million government investment in Patient Recruitment Centres for commercial clinical research

NHS patients will benefit from easier access to clinical research opportunities, following a £7 million government investment to launch five new regional Patient Recruitment Centres (PRCs) across England. The five new centres are distributed across the country to provide opportunities for patients in regions across England who may not previously have been able to take…

Details

No improvement in death rate for COVID-19 patients who received hydroxychloroquine

Boston, MA — A research team led by investigators from Brigham and Women’s Hospital has evaluated real-world evidence related to outcomes for COVID-19 patients who were treated with hydroxychloroquine or chloroquine analogues (with or without a macrolide). Investigators found no evidence that either drug regimen reduced the death rate among patients. Patients treated with hydroxychloroquine…

Details